ReviewCurrent oncology (Toronto, Ont.)2021
Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges.
Review in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06648746 (Predictors of Therapeutic Success and Adverse Events in Endoscopic Ampullectomy), which is not on this map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Predictors of Therapeutic Success and Adverse Events in Endoscopic Ampullectomy
Who cites it
42 citing papers in PubMed.
- Isolated extreme gamma-glutamyl transferase elevation as an early indicator of ampullary adenocarcinoma in a young adult: a case report with molecular insights.BMC gastroenterology · 2026Article
- Extrahepatic biliary obstruction due to ampullary carcinoma in a dog.The Journal of veterinary medical science · 2026Article
- Deciphering the single-cell molecular landscape of ampullary cancer: A rare gastrointestinal malignancy.iScience · 2026Article
- AI-assisted improvement of endoscopic diagnosis of ampullary lesions.NPJ digital medicine · 2026Article
- Article
- Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas.International journal of molecular sciences · 2026Review
- Advanced ampullary cancer: post-hoc analysis of the ABC-01, ABC-02, and ABC-03 clinical trials.The oncologist · 2026Article
- Gemcitabine-Based versus Fluoropyrimidine-Based Chemotherapy and Role of Platinum Combination for First-Line Palliative Systemic Treatment in Advanced Ampullary Adenocarcinoma.Cancer management and research · 2026Article
- Review
- Evaluating the Role of Morphological Subtypes in the Classification of Periampullary Adenocarcinomas.Cancers · 2025Article
- Differentiation of non-ampullary duodenal carcinoma from intestinal-type ampullary carcinoma by tailored multidetector CT: utility of four imaging criteria.European radiology · 2025Article
- Identifying occult high-risk features and stratified management strategies following curative resection for ampullary adenocarcinoma.Cancer biology & medicine · 2025Article
- Incidental multifocal pancreatic neuroendocrine tumors: A rare synchronous conundrum with intra-ampullary and peri-ampullary adenocarcinoma.Medical journal, Armed Forces India · 2025Article
- Optimizing postoperative chemotherapy for ampullary cancer: A risk-driven approach to precision care.iLIVER · 2025Article
- Article
- Adenocarcinoma of the duodenal papilla with synchronous peritoneal metastases-5 years of overall survival: A case report.World journal of clinical oncology · 2025Article
- Neuroendocrine carcinoma causing common bile duct obstruction: a case report.Oxford medical case reports · 2025Article
- Integrated proteogenomic characterization of ampullary adenocarcinoma.Cell discovery · 2025Article
- Defying the Prognostic Odds: A Case Report of Unexpected Complete Remission of Metastatic Ampullary Carcinoma With Palliative Chemotherapy.Case reports in oncological medicine · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ampullary carcinomas (ACs) represent a rare entity, accounting for approximately 0.2% of all gastrointestinal solid tumors and 20% of all periampullary cancers (PACs). Unfortunately, few data are available regarding the optimal therapeutic strategy for ACs due to their rarity, and physicians frequently encounter significant difficulties in the management of these malignancies. In this review, we will provide an overview of current evidence on AC, especially focusing on biological features, histological characteristics, and available data guiding present and future therapeutic strategies for these rare, and still barely known, tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.